On Thursday, Shares of General Motors Company (NYSE:GM), included 0.57 % and shut at $33.42 inside the end purchasing and offering session. The last exchanging scope of the stock ranges amongst $32.75 and $33.44. General Motors Company designs, builds, and sells cars, crossovers, trucks, and automobile parts worldwide. The company operates through GM North America, GM Europe, GM International Operations, GM South America, and GM Financial segments. It markets its vehicles mainly under the Buick, Cadillac, Chevrolet, GMC, Opel, Holden, Vauxhall, Baojun, Jiefang, and Wuling brand names. The company also sells cars and trucks to dealers for consumer retail sales, in addition to to fleet customers, counting daily rental car companies, commercial fleet customers, leasing companies, and governments. In addition, it offers connected safety, security and mobility solutions, and information technology services. The company, through its partner, General Motors Financial Company, Inc., provides automotive financing services.
Shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH), subtract -15.31% and shut at $3.43 inside the last exchanging session. The rest of the purchasing and offering scope of the stock levels among $3.39 and $4.12. The association’s commercial center capitalization is $160.89 million with the general uncommon loads of 39.73 million. Aurinia Pharmaceuticals Inc. (AUPH) (AUP.TO) (“Aurinia” or the “Company”), a clinical stage biopharmaceutical company focused on the global immunology market, recently highlighted additional findings from its global Phase IIb AURA study of voclosporin in the treatment of lupus nephritis (LN). The abstract was presented at the American College of Rheumatology and Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting in Washington, D.C. during the Late-Breaking News session on November 15, 2016.
The late-breaking abstract, titled, “Speed of Remission with the Use of Voclosporin, MMF and Low Dose Steroids: Results of a Global Lupus Nephritis Study,” was presented by Mary Anne Dooley, M.D., M.P.H., of the University of North Carolina Kidney Center. The global Phase IIb AURA study of voclosporin, a novel immunosuppressant that has been applied as a treatment for LN, is the first global active lupus nephritis study to meet its primary endpoint. In addition, all secondary endpoints in AURA were met, counting demonstrating a more rapid response rate for patients receiving voclosporin as compared to patients in the control arm with most patients achieving complete remission (CR) at or before the eighth week of the trial.